Biotech · Private company
Revimmune
Track this companyFree. Adds Revimmune to your Dealase workspace and tells you when its record changes.
Clinical trials61 recruiting or active
Pipeline programs4From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline4
- CYT107Phase 2 · COVID-19ClinicalTrials.gov · fetched Nov 12, 2026
- CYT107Phase 2 · Sepsis, SevereClinicalTrials.gov · fetched Nov 12, 2026
- Interleukin-7Phase 2 · Severe Sepsis With Septic ShockClinicalTrials.gov · fetched Nov 12, 2026
- Recombinant human interleukin-7Phase 2 · Mycobacterium Infections, NontuberculousClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials6
- Impact of Recombinant Human Interleukin-7 (CYT107) on Tumor Clearance and Immune Reconstitution in Multiple Myeloma Patients After Autologous Hematopoietic Cell TransplantPHASE1 · ACTIVE_NOT_RECRUITING · started Apr 4, 2025ClinicalTrials.gov NCT06523699 · fetched Nov 12, 2026
- InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic Patients With COVID-19 Infection ( ILIAD-7-US-O )PHASE2 · TERMINATED · started Dec 20, 2020ClinicalTrials.gov NCT04426201 · fetched Nov 12, 2026
- Recombinant Interleukin-7 (CYT107) to Treat Patients With Refractory Nontuberculous Mycobacterial Lung DiseasePHASE2 · TERMINATED · started Nov 30, 2020ClinicalTrials.gov NCT04154826 · fetched Nov 12, 2026
- InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection ( ILIAD-7-US-I )PHASE2 · TERMINATED · started Sep 15, 2020ClinicalTrials.gov NCT04442178 · fetched Nov 12, 2026
- Recombinant Interleukin-7 (CYT107) to Restore Absolute Lymphocyte Counts in Sepsis PatientsPHASE2 · TERMINATED · started Jun 1, 2019ClinicalTrials.gov NCT03821038 · fetched Nov 12, 2026
- A Study of IL-7 to Restore Absolute Lymphocyte Counts in Sepsis PatientsPHASE2 · COMPLETED · started Jan 1, 2016ClinicalTrials.gov NCT02640807 · fetched Nov 12, 2026